Cash/Burn From SEC Filing For Period: 

Q1 '20

VNDA

Vanda Pharmaceuticals Inc.

Vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.

Cash

$58M

Burn Rate

-$0.5M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

HETLIOZ® (tasimelteon)

Jet Lag Disorder

Report out on post-CRL FDA meeting

November 6, 2020 (Est)

Fanapt® (iloperidone)

Schizophrenia

Quarterly Sales (Approved)

November 6, 2020 (Est)

HETLIOZ® (tasimelteon)

Non-24-Hour Sleep-Wake Disorder (Non-24)

Quarterly Sales (Approved)

November 6, 2020 (Est)

HETLIOZ® (tasimelteon)

Smith-Magenis Syndrome (SMS)

PDUFA

December 1, 2020

Tradipitant | ODYSSEY VLY-686-3501

COVID-19

Phase 3 (Interim Analysis & Safety and Efficacy Data)

September 2020

Tradipitant

Pruritus in Atopic Dermatitis | EPIONE

Phase 3

TBD

Tradipitant

Motion Sickness

Phase 3

TBD

Tradipitant

Gastroparesis

NDA Filing

2021

Trichostatin A (VTR-297)

Relapsed or Refractory Hematologic Malignancies

Phase 1

TBD

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon